ESR1 and breast cancer: The clinical management of ER+ BC (mainly Luminal A and Luminal B) includes endocrine therapy (ER downregulators, selective ER modulators, and aromatase inhibitors) as primary treatment, albeit luminal B tumors are mainly treated with chemotherapy due to lower sensitivity to endocrine therapy (71).